Study identity card

Pfizer C5091017

Argentina Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany Japan Mexico Slovakia South Africa South Korea Spain Taiwan Türkiye United States of America
Share
  • Study type: Randomised Clinical Trial, Treatment
  • Study type descriptors: Randomised controlled trial, Multicentre
  • Objective: To evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease
  • Number of participants enrolled: Enrollment ongoing
  • Study enrolling from to
  • Study includes follow-up for 34 days

Study Data

  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Outpatient clinic
  • Primary care
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Ibuzatrelvir

Other information

If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it

The data is updated up to